Eledon Pharmaceuticals, Inc.
corporate_fare Company Profile
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for ELDN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for ELDN spans 10-Q, 8-K, S-3, PRE 14A.
Recent high-impact activity:
- Eledon Posts $69.7M Cash, Runway to Q2 2027 as Q3 Loss Widens Ex-Warrant Gain
- Eledon 10-Q: $69.7M Cash and Going-Concern Doubt Ahead of Phase 3 LEGACY
- Eledon Posts Q3 Loss, $69.7M Cash Into Q2 2027, Phase 3 LEGACY Set for Q4
- Tegoprubart Beats Tacrolimus on 12-Month Quality-of-Life Measures in Phase 2
- Eledon's Tegoprubart Shows Durable Kidney Function, Wins FDA Fast Track
Financial Snapshot
Short Interest & Short Volume
7.51 days to coverFINRA reported short interest of 8,253,430 shares in ELDN as of the October 30, 2026 settlement, a 4.5% increase from the prior period — about 7.5 days to cover at its recent average daily volume. On November 20, 2026, 70.3% of ELDN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.